Pfizer completes Metsera acquisition in deal worth up to $10 bn / Photo: ANGELA WEISS - AFP/File
-
Morikawa says LIV players face 'business decision' after Rahm exit
-
North Korea demands South show 'utmost respect' to restore relations
-
Tenzing Norgay's son says Himalayas sending climate warning
-
Saudi says three dead in airport attacks claimed by Houthis
-
On your bike! Bottas opts for two wheels to reach Singapore GP
-
'Mad dream': New showcase for African film opens in London
-
Alcaraz, Sinner, Osaka commit to Australian Open '1 Point Slam'
-
All Blacks coach Rennie says Wallabies exit 'part of the game'
-
Dodgers beat Braves to advance in MLB playoffs, Rays oust Yankees
-
The growing protests against India's poll body - and PM Modi
-
'A sun as black as my lungs': how corruption crucified a polluted Albania city
-
Stocks fall further as oil spike fans fresh inflation worries
-
The British historian helping the French rediscover de Gaulle
-
Bad COP, worse COP? EU tempers hopes for UN climate summit
-
Dodgers beat Braves to advance, Guardians survive in MLB playoffs
-
Rookie Henry named in Wallabies midfield to face All Blacks
-
Latin American, Caribbean women top Nobel literature buzz
-
Housing crisis set to dominate Spain's snap election
-
US says Fiji-based Chinese official paid bribes for Beijing
-
Gas, health care, utilities: high costs squeeze US midterm voters
-
After botched US execution, Christa Pike was nearly taken off life support
-
New Zealand Rugby seeks injunction over PNG Chiefs name
-
Guinea-Bissau junta urges military unit loyal to ex-president to disarm
-
Samsung expects 780% quarterly operating profit jump on AI boom
-
As species decline, green turtles offer glimmer of hope
-
Guardians survive with 9-3 win over White Sox
-
Brothers Scott and Beauden Barrett named to start for All Blacks
-
Saudi Arabia says 3 dead at airports after Houthis claim attacks
-
EU trade chief seeks to dial down China tensions
-
Stocks slide as oil sees volatile trading day over Iran war fears
-
'Never again Bolsonaro': thousands march ahead of Brazil election runoff
-
Microsoft pushes AI vision with new, expensive Surface laptop
-
After botched execution, US woman was nearly taken off life support before revival
-
Five children among 28 killed in Russian strikes on Ukraine
-
Searing AIDS drama 'Elsinore' opens London film festival
-
Odell Beckham Jr signs with Minnesota Vikings
-
Evicted pensioner who sparked Spain housing protests dies: tenant union
-
Saudi Arabia says three dead at airports after Houthis claim attacks
-
Golf star Rahm quitting LIV tour over 'unacceptable' terms
-
Trump plans to turn Florida golf course into presidential retreat
-
Thousands march fearing return of a Bolsonaro presidency in Brazil
-
WHO says cannot conduct full risk assessment on Russia plague reports
-
French PM denies police ordered to confront student protesters
-
After botched execution, US woman is awake and shackled to bed
-
Rubio touts US power, calls on Europe to emerge from 'slumber'
-
New Zealand fly-half Mo'unga ruled out of Australia Tests
-
Trump says 'we don't think' Russian plague is bio-weapon
-
Protests in major Turkish city after mayor defects to Erdogan party
-
Five children among 26 killed in Ukraine after Russian strikes
-
Climate change strips island's title of largest penguin colony: study
Pfizer completes Metsera acquisition in deal worth up to $10 bn
US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.
The approval from Metsera's shareholders opens the door for Pfizer to make inroads into the fast-growing market for weight loss drugs.
Metsera, a US company specializing in obesity treatments, had been the subject of escalating offers from Pfizer and Danish challenger Novo Nordisk, which makes the weight loss drug Wegovy and Ozempic, a diabetes medication with weight loss benefits.
Pfizer said in a statement that its acquisition was successfully completed.
It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.
This involved $65.60 per share in cash, and an additional $20.65 per share linked to the success of its drug pipeline.
"By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it," said Pfizer chief executive Albert Bourla.
"We look forward to combining Metsera's innovative portfolio with our global development, manufacturing and commercial infrastructure," he added.
The potential sale of Metsera to Novo Nordisk had drawn scrutiny over potential antitrust implications.
L.AbuTayeh--SF-PST
